BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > Sinovac

<< Previous

Bullboard Posts

Next >>

Comment by frankmanon Jan 13, 2021 10:01am

136 Views

Post# 32284005

RE:Sinovac

There are many other markets in Asia as well.BioVaxys is looking into.

Today's WSJ is running an article on a Brazilian clinical study finding that the COVID-19 vaccine from Sinovac in China is almost 30 points less effective than origially claimed. A very good reason for continued development efforts behind new SARS2 vaccines. No way is this 'game over' with just two mRNA vaccines available.

Here is the link
https://www.wsj.com/articles/chinas-sinovac-covid-19-vaccine-is-50-4-in-late-stage-brazil-trials-11610470581?mod=latest_headlines

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity